Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Advances in Experimental Medicine and Biology|October 29, 2020
Regulatory T Cells in the Tumor MicroenvironmentRebekah E Dadey, Creg J Workman, Dario A A Vignali
Immunohorizons|January 23, 2021
Regulatory T Cell-Derived TRAIL Is Not Required for Peripheral ToleranceRebekah E Dadey, Stephanie Grebinoski, Qianxia Zhang, et al.
Immunohorizons|February 18, 2025
Regulatory T cells in the tumor microenvironment display a unique chromatin accessibility profileRebekah E Dadey, Jian Cui, Dhivyaa Rajasundaram, et al.
The Journal of Clinical Investigation|May 15, 2023
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastasesMark C Korpics, Benjamin E Onderdonk, Rebekah E Dadey, et al.
Journal for Immunotherapy of Cancer|June 15, 2025
Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinomaRebekah E Dadey, Ruxuan Li, Jake Griner, et al.
Cell|May 30, 2017
Interferon-γ Drives T<sub>reg</sub> Fragility to Promote Anti-tumor ImmunityAbigail E Overacre-Delgoffe, Maria Chikina, Rebekah E Dadey, et al.
Medrxiv : the Preprint Server for Health Sciences|May 7, 2024
Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanomaAlexandra Tompkins, Zane N Gray, Rebekah E Dadey, et al.
Journal for Immunotherapy of Cancer|February 12, 2025
Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanomaAlexandra G Tompkins, Zane N Gray, Rebekah E Dadey, et al.
Medrxiv : the Preprint Server for Health Sciences|August 8, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsMatthew K Nguyen, Mark Jelinek, Arjun Singh, et al.
Pageof 2